INS 1007

Drug Profile

INS 1007

Alternative Names: AZD 7986; INS1007

Latest Information Update: 06 Oct 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Anti-inflammatories; Antibronchitics; Small molecules
  • Mechanism of Action Dipeptidyl peptidase I inhibitors; Leucocyte elastase modulators; Neutrophil modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic obstructive pulmonary disease

Most Recent Events

  • 05 Oct 2016 Insmed plans a phase II trial for Non-cystic fibrosis bronchiectasis
  • 05 Oct 2016 INS 007 (previously AZD 7986) licensed to Insmed worldwide
  • 05 Oct 2016 Insmed plans a phase II trial for Bronchiectasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top